<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937832</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ04104-3-CTF</org_study_id>
    <nct_id>NCT01937832</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia</brief_title>
  <official_title>A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and Efficacy of Faropenem in&#xD;
      community-acquired pneumonia (CAP) subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per subject clinical cure rate</measure>
    <time_frame>7-14 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Faropenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faropenem</intervention_name>
    <description>dosage form: Injection dosage:1200 mg frequency: Three times a day</description>
    <arm_group_label>Faropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>dosage form: Injection dosage:1000 mg frequency: once a day</description>
    <arm_group_label>Ertapenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged between18~73 years, either male or female&#xD;
&#xD;
          2. Patients requiring hospitalization or emergency room observation, and the need to&#xD;
             receive intravenous antibiotic treatment&#xD;
&#xD;
          3. Women of childbearing age having negative pregnancy test at the time of enrollment and&#xD;
             agreeing to take effective contraceptive measures from the delivery to 7 ~14 days&#xD;
             after stopping .(for example: oral contraception, injectable contraception, or implant&#xD;
             contraception , spermicides and condoms, or IUDs).&#xD;
&#xD;
          4. Comply with the following clinical, radiological and microbiological criteria of&#xD;
             Community-Acquired Pneumonia(CAP)&#xD;
&#xD;
          5. Patients had used ineffective systemic antimicrobial drugs before enrollment or had&#xD;
             effective antimicrobial drugs within 72h before enrollment, used &lt;24h&#xD;
&#xD;
          6. Informed consent granted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with atypical pneumonia infected by the Mycoplasma pneumoniae, Chlamydia&#xD;
             pneumoniae, Legionella pneumophila bacteria;&#xD;
&#xD;
          2. Patients infected by pathogens MRSA, Pseudomonas aeruginosa or Acinetobacter&#xD;
             baumannii;&#xD;
&#xD;
          3. Viral pneumonia;&#xD;
&#xD;
          4. Aspiration pneumonia;&#xD;
&#xD;
          5. Hospital-acquired pneumonia, including ventilator-associated pneumonia;&#xD;
&#xD;
          6. Patients with Severe pneumonia who meet one primary criterion or three secondary&#xD;
             criteria (See Appendix);&#xD;
&#xD;
          7. Patients with a rapid progressive or end-stage disease, and can not survive until the&#xD;
             end of the study period by antibiotic treatment;&#xD;
&#xD;
          8. Patients with bronchial obstruction or a history of obstructive pneumonia (not&#xD;
             including chronic obstructive pulmonary disease);&#xD;
&#xD;
          9. Suffering from any of the following diseases: active tuberculosis, bronchiectasis,&#xD;
             lung abscess, lung cancer, non-infectious interstitial lung disease, pulmonary edema,&#xD;
             atelectasis, pulmonary embolism, pulmonary eosinophil infiltration disease and&#xD;
             pulmonary vasculitis;&#xD;
&#xD;
         10. Infections acquired from hospitals, nursing homes or other long-term care facilities,&#xD;
             or patients hospitalized within 14 days prior to enrollment ;&#xD;
&#xD;
         11. Allergic to penem and carbapenem antibiotic;&#xD;
&#xD;
         12. Pregnancy or lactation in women;&#xD;
&#xD;
         13. Patients with uncontrolled psychiatric history or those at risk of suicide two years&#xD;
             prior to enrollment;&#xD;
&#xD;
         14. A history of epilepsy or other central nervous system disorders in patients;&#xD;
&#xD;
         15. Patients with Renal dysfunction, screening serum creatinine values above the upper&#xD;
             limit of normal 10%;&#xD;
&#xD;
         16. The Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is 3&#xD;
             times the upper limit of the reference value, or total bilirubin beyond the upper&#xD;
             limit of the normal range by 10% ;&#xD;
&#xD;
         17. Serious diseases that affecting the immune system, such as: a human immunodeficiency&#xD;
             virus (HIV) infection history, or CD4 + T-lymphocyte count &lt;200/200/mm3, or&#xD;
             Neutrophilic granulocytopenia (neutrophil count &lt;1500/mm3), or hematologic&#xD;
             malignancies or solid organ or splenectomy, etc;&#xD;
&#xD;
         18. Patients who are taking steroid medications, at least 20mg daily dose of prednisone(or&#xD;
             equivalent doses of other glucocorticoids);&#xD;
&#xD;
         19. Patients who are accepting chemotherapy drug therapy or anti-cancer therapy, or plan&#xD;
             to accept such treatment during the trial six months prior to enrollment;&#xD;
&#xD;
         20. Alcohol or illicit drug abuse history;&#xD;
&#xD;
         21. Patients who have accepted any other experimental drugs within 3 months prior to&#xD;
             enrollment;&#xD;
&#xD;
         22. more than 500ml blood donation within 3 months prior to enrollment;&#xD;
&#xD;
         23. Patients who have participated in this clinical trial ever before;&#xD;
&#xD;
         24. Combined use of other antibacterial drugs in patients;&#xD;
&#xD;
         25. Patients are diagnosed to have potential increased risks, or there may be interference&#xD;
             with clinical trials;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wu Ju Fang</last_name>
    <phone>13816357099</phone>
    <email>Wujf53@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taihe Hospital in Shiyan City</name>
      <address>
        <city>Shiyan</city>
        <state>Hubei</state>
        <zip>442000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital ,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Wu Ju fang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

